Delayed thyroid-stimulating hormone suppression by L-thyroxine in the management of differentiated thyroid carcinoma.

[1]  D. Wynford‐Thomas,et al.  Control of human thyroid follicular cell proliferation in suspension and monolayer culture , 1987, Molecular and Cellular Endocrinology.

[2]  A. Pinchera,et al.  Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. , 1987, The Journal of clinical endocrinology and metabolism.

[3]  M. Girelli,et al.  Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine , 1983, Journal of endocrinological investigation.

[4]  K. Liewendahl,et al.  Suppression of the TSH response to TRH by thyroxine therapy in differentiated thyroid carcinoma patients. , 1979, Acta Endocrinologica.

[5]  B. D. Thompson,et al.  Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. , 1977, The British journal of radiology.

[6]  M. Surks,et al.  Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy. , 1977, The Journal of clinical endocrinology and metabolism.

[7]  W. Kemmerer,et al.  PAPILLARY THYROID CARCINOMA: THE IMPACT OF THERAPY IN 576 PATIENTS , 1977, Medicine.

[8]  W. P. Greening,et al.  Treatment of thyroid cancer in 293 patients , 1976, The British journal of surgery.

[9]  M. Hüfner,et al.  [Principals of hormone substitution in thyrectomized patients with carcinoma of the thyroid gland (author's transl)]. , 1975, Der Radiologe.